Global Erythropoietin Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4431876
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Amgen, Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • F. Hoffman-La Roche Ltd.
  • Hospira, Inc.
  • Johnson & Johnson, Inc.
  • MORE
Erythropoietin Drugs Market - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025, the global erythropoietin drugs market was valued at US$ 9,097.7 Mn in 2016, and is expected to reach US$ 19,653.2 Mn by 2025, expanding at a CAGR of 9% from 2017 to 2025.

Market Insights

According to the Centers for Disease Control and Prevention (CDC), around 5.5 Mn ambulatory care patients suffer from anemia due to a nutritional deficiency, while chronic disease is the second most prevalent cause. Even though anemia is a common symptom in chronic disease, it still goes underdiagnosed and undertreated, especially in chronic kidney disease (CKD) patients not undergoing dialysis anemia is undertreated. In U.S., around 20 Mn people suffer from CKD, out of which 2-4 million have anemia. Anemia increases substantial economic burden and also affects quality of life. Rising incidence of CKD, cancer and HIV is the major factor fuelling the demand of erythropoietin drugs. Advancement in recombinant DNA technology has led to introduction of different forms of drugs such as epoetin-beta, darbepoetin-alfa and others. Biologics currently dominate the erythropoietin drugs market; but the entry of novel drugs with biosimilar formulations with better efficacy and cost effectiveness would present lucrative opportunities. Biosimilars would be a fast growing market, especially in developing countries in Asia Pacific and Middle East & Africa, due to low cost therapeutics and enhanced efficacy.

The global erythropoietin drugs market is segmented by drug type into epoetin-alfa, epoetin-beta, darbepoetin-alfa and others. Epoetin-alfa dominates the global erythropoietin drugs market, since it is the first biologic for anemia caused due to kidney disease, cancer or HIV and is widely accepted by physicians. The global erythropoietin drugs market is segmented by application type into anemia (cancer and HIV), kidney disorders (ESRD and dialysis) and others (neural diseases, wound healing and others). Renal disease occupies a large share of the market due to the reported increase in prevalence of kidney disorders.

As of the current market scenario, North America dominated the global erythropoietin drugs market followed by the European market. Rising prevalence of renal disease, cancer and HIV, well established research and healthcare infrastructure, favorable reimbursement policies are the key factors driving the North American market. Additionally, major biopharmaceutical and biotechnological companies are based in this region, further fuelling the erythropoietin drugs market. Asia Pacific is the fastest growing erythropoietin drugs market in forecast period. It would be the most lucrative market for biosimilars with low cost of therapy and rising prevalence of chronic diseases.

Market Competition Assessment

Key players in the global erythropoietin drugs market are Amgen, Inc., Biocon Limited, Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffman-La Roche Ltd., Hospira, Inc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Inc., LG Life Sciences Ltd., Ranbaxy Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and others

Key Market Movements:
  • According to Kidney Disease Statistics for the United States, prevalence of CKD in the general population is around 14 percent, which is one the main drivers for growth of erythropoietin drugs market
  • In cancer patients almost 77% suffer from anemia, which is often overlooked as fatigue is not generally not reported. Anemia is generally associated with cancer due to chemotherapy treatment, blood loss, marrow tumor, nutritional deficiency, but is mostly caused due to cytokine production.
  • There is being a general increase in trend of incidence of anemia with disease progression from HIV to autoimmune immunodeficiency syndrome (AIDS)
  • With rise in R&D of biosimilars, pipeline drugs would further drive the market. Cadila Healthcare’s (Zydus Cadila) Zyan1, an oral molecule used to treat anemia associated with chronic kidney disease (CKD) is under phase two trial. Roxadustat, is first-in-class drug for anemia caused by CKD, developed by FibroGen and AstraZeneca, in phase III studies in China and will be filed for approval before the end of 2017. GlaxoSmithKline's daprodustat and Akebia/Takeda's vadadustat, is also in phase III testing which might be the first oral alternative to injectable EPO for anemia
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen, Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • F. Hoffman-La Roche Ltd.
  • Hospira, Inc.
  • Johnson & Johnson, Inc.
  • MORE
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Erythropoietin Drugs Market Portraiture
2.1.1. Global Erythropoietin Drugs Market, by Drug, 2016
2.1.2. Global Erythropoietin Drugs Market, by Application, 2016
2.1.3. Global Erythropoietin Drugs Market, by Geography, 2016

Chapter 3. Erythropoietin Drugs Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.4.1. Attractive Investment Proposition, by Geography
3.5. Competitive Landscape
3.5.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Erythropoietin Drugs Market, by Drug Type, 2015 - 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Erythropoietin Drugs Market, by Drug Type
4.3. Epoetin-alfa
4.4. Epoetin-beta
4.5. Darbepoetin-alfa
4.6. Others
4.7. Tabular Representation of Phase III, II and I Erythropoietin Drugs

Chapter 5. Global Erythropoietin Drugs Market, by Application Type, 2015 - 2025 (US$ Mn)
5.1. Overview
5.2. Attractive Investment Proposition: Global Erythropoietin Drugs Market, by Application Type
5.3. Anemia
5.3.1. Cancer
5.3.2. HIV
5.4. Kidney Disorders
5.5. Others

Chapter 6. Global Erythropoietin Drugs Market, by Geography, 2015 - 2025 (US$ Mn)
6.1. Overview
6.2. North America Erythropoietin Drugs Market Analysis, 2015 - 2025
6.2.1. North America Erythropoietin Drugs Market, by Drug Type, 2015 - 2025 (US$ Mn)
6.2.2. North America Erythropoietin Drugs Market, by Application Type, 2015 - 2025 (US$ Mn)
6.2.3. North America Erythropoietin Drugs Market, by Country, 2015 - 2025 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Erythropoietin Drugs Market Analysis, 2015 - 2025
6.3.1. Europe Erythropoietin Drugs Market, by Drug Type, 2015 - 2025 (US$ Mn)
6.3.2. Europe Erythropoietin Drugs Market, by Application Type, 2015 - 2025 (US$ Mn)
6.3.3. Europe Erythropoietin Drugs Market, by Country, 2015 - 2025 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. France
6.3.3.4. Rest of Europe
6.4. Asia Pacific Erythropoietin Drugs Market Analysis, 2015 - 2025
6.4.1. Asia Pacific Erythropoietin Drugs Market, by Drug Type, 2015 - 2025 (US$ Mn)
6.4.2. Asia Pacific Erythropoietin Drugs Market, by Application Type, 2015 - 2025 (US$ Mn)
6.4.3. Asia Pacific Erythropoietin Drugs Market, by Country, 2015 - 2025 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. India
6.4.3.4. Rest of APAC
6.5. Latin America Erythropoietin Drugs Market Analysis, 2015 - 2025
6.5.1. Latin America Erythropoietin Drugs Market, by Drug Type, 2015 - 2025 (US$ Mn)
6.5.2. Latin America Erythropoietin Drugs Market, by Application Type, 2015 - 2025 (US$ Mn)
6.5.3. Latin America Erythropoietin Drugs Market, by Country, 2015 - 2025 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Erythropoietin Drugs Market Analysis, 2015 - 2025
6.6.1. MEA Erythropoietin Drugs Market, by Drug Type, 2015 - 2025 (US$ Mn)
6.6.2. MEA Erythropoietin Drugs Market, by Application Type, 2015 - 2025 (US$ Mn)
6.6.3. MEA Erythropoietin Drugs Market, by Region, 2015 - 2025 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Amgen, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Biocon Limited
7.3. Celltrion, Inc.
7.4. Dr. Reddy’s Laboratories Ltd.
7.5. F. Hoffman-La Roche Ltd.
7.6. Hospira, Inc.
7.7. Intas Pharmaceuticals Ltd.
7.8. Johnson & Johnson, Inc.
7.9. LG Life Sciences Ltd.
7.10. Ranbaxy Laboratories Ltd.
7.11. Sun Pharmaceutical Industries Ltd.
7.12. Teva Pharmaceutical Industries Ltd.
7.13. Other Notable Players

List of Figures
Fig. 1 Erythropoietin Drugs: Market Segmentation
Fig. 2 Global Erythropoietin Drugs Market Share, by Drug Type, 2016 (US$ Mn)
Fig. 3 Global Erythropoietin Drugs Market Share, by Application Type, 2016 (US$ Mn)
Fig. 4 Global Erythropoietin Drugs Market, by Geography, 2016 (Value %)
Fig. 5 Attractive Investment Proposition, by Geography
Fig. 6 Market Competition Landscape, by Key Players, 2016
Fig. 7 Global Erythropoietin Drugs - Epoetin-alfa Market, 2015 - 2025 (US$ Mn)
Fig. 8 Global Erythropoietin Drugs - Epoetin-beta Market, 2015 - 2025 (US$ Mn)
Fig. 9 Global Erythropoietin Drugs - Darbepoetin-alfa Market, 2015 - 2025 (US$ Mn)
Fig. 10 Global Others Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 11 Global Erythropoietin Drugs for Cancer Market, 2015 - 2025 (US$ Mn)
Fig. 12 Global Erythropoietin Drugs for HIV Market, 2015 - 2025 (US$ Mn)
Fig. 13 Global Erythropoietin Drugs Kidney Disorder Market, 2015 - 2025 (US$ Mn)
Fig. 14 Global Other Application Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 15 U.S. Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 16 Canada Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 17 U.K. Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 18 Germany Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 19 France Erythropoietin Drugs Market, 2015-2025 (US$ Mn)
Fig. 20 Rest of Europe Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 21 Japan Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 22 China Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 23 India Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 24 Rest of Asia Pacific Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 25 Brazil Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 26 Mexico Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 27 Rest of Latin America Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 28 GCC Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 29 Rest of Middle East and Africa Erythropoietin Drugs Market, 2015 - 2025 (US$ Mn)

List of Tables
Table 1 Global Erythropoietin Drugs Market, by Drug Type, 2015 - 2025 (US$ Mn)
Table 2 Global Erythropoietin Drugs Market, by Application Type, 2015 - 2025 (US$ Mn)
Table 3 North America Erythropoietin Drugs Market, by Drug Type, 2015 - 2025 (US$ Mn)
Table 4 North America Erythropoietin Drugs Market, by Application Type, 2015 - 2025 (US$ Mn)
Table 5 North America Erythropoietin Drugs Market, by Country, 2015 - 2025 (US$ Mn)
Table 6 Europe Erythropoietin Drugs Market, by Drug Type, 2015 - 2025 (US$ Mn)
Table 7 Europe Erythropoietin Drugs Market, by Application Type, 2015 - 2025 (US$ Mn)
Table 8 Europe Erythropoietin Drugs Market, by Country, 2015 - 2025 (US$ Mn)
Table 9 Asia Pacific Erythropoietin Drugs Market, by Drug Type, 2015 - 2025(US$ Mn)
Table 10 Asia Pacific Erythropoietin Drugs Market, by Application Type, 2015 - 2025(US$ Mn)
Table 11 Asia Pacific Erythropoietin Drugs Market, by Country, 2015 - 2025(US$ Mn)
Table 12 Latin America Erythropoietin Drugs Market, by Drug Type, 2015 - 2025(US$ Mn)
Table 13 Latin America Erythropoietin Drugs Market, by Application Type, 2015 - 2025(US$ Mn)
Table 14 Latin America Erythropoietin Drugs Market, by Country, 2015 - 2025 (US$ Mn)
Table 15 Middle East and Africa Erythropoietin Drugs Market, by Drug Type, 2015 - 2025 (US$ Mn)
Table 16 Middle East and Africa Erythropoietin Drugs Market, by Application Type, 2015 - 2025 (US$ Mn)
Table 17 Middle East and Africa Erythropoietin Drugs Market, by Region, 2015 - 2025 (US$ Mn)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amgen, Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffman-La Roche Ltd.
  • Hospira, Inc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson, Inc.
  • LG Life Sciences Ltd.
  • Ranbaxy Laboratories Ltd.
  • Sun Pharmace
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll